# EDGAR Filing Document

**Accession Number:** 0001822791
**File Stem:** 0001437749-26-018269
**Filing Date:** 2026-5
**Character Count:** 6138
**Document Hash:** 3c6da0ce5d171d9488b5c3be26431a59
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-018269.hdr.sgml**: 20260522

**ACCESSION NUMBER**: 0001437749-26-018269

**CONFORMED SUBMISSION TYPE**: SD

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260522

**DATE AS OF CHANGE**: 20260522

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Clene Inc.
- **CENTRAL INDEX KEY:** 0001822791
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 852828339
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SD
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39834
- **FILM NUMBER:** 261014682

**BUSINESS ADDRESS:**
- **STREET 1:** 6550 SOUTH MILLROCK DRIVE, SUITE G50
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84121
- **BUSINESS PHONE:** 801-676-9695

**MAIL ADDRESS:**
- **STREET 1:** 6550 SOUTH MILLROCK DRIVE, SUITE G50
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chelsea Worldwide Inc.
- **DATE OF NAME CHANGE:** 20200827

------

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM SD**

**SPECIALIZED DISCLOSURE REPORT**

------

**CLENE INC.**

(Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39834** | **85-2828339** |
| (State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer |
| incorporation or organization) |  | Identification No.) |
| **6550 South Millrock Drive, Suite G50**<br> **Salt Lake City, Utah** |  | **84121** |
| (Address of principal executive offices) |  | (Zip code) |

---

**Jerry Miraglia, (443) 273-1645**

(Name and telephone number, including area code,

of the person to contact in connection with this report.)

Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:

☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended December 31, 2025.

------

**Section 1** – **Conflict Minerals Disclosure**

**Item 1.01 Conflict Minerals Disclosure and Report**

This Specialized Disclosure Form of Clene Inc. (the "Company") is being filed in accordance with Rule 13p-1 (the "Rule") under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2025 to December 31, 2025 (the "Relevant Period"). The Rule imposes disclosure requirements of certain information when a company manufactures or contracts to manufacture products for which Conflict Minerals are necessary to the functionality or production of those products. The term "Conflict Minerals" means columbite-tantalite (coltan), cassiterite, gold, wolframite, or their derivatives, which are limited to tantalum, tin, and tungsten, or any other mineral or its derivatives determined by the Secretary of State to be financing conflict in the Democratic Republic of the Congo or an adjoining country (the "Covered Countries").

During the Relevant Period, the Company determined a Conflict Mineral, gold, was necessary to the functionality or production of its products.

***Conflict Minerals Disclosure***

The Company conducted a reasonable country of origin inquiry regarding the origin of gold used in its products during the Relevant Period. The Company's reasonable country of origin inquiry consisted of (i) identifying all suppliers of gold to the Company, which consisted of one supplier during the Relevant Period, (ii) requesting that each gold supplier complete the Responsible Minerals Initiative ("RMI") Conflict Minerals Reporting Template ("CMRT"), a standardized reporting template developed by RMI to collect sourcing information on Conflict Minerals, and (iii) reviewing the supplier response and CMRT and performing any follow-up procedures or clarification as deemed necessary. The Company received a response from its gold supplier which included 45 other smelters that it sourced gold from during the Relevant Period, which the Company cross-referenced against the RMI Conformant Smelter List without exception. The RMI Conformant Smelter List is a list of smelters who have successfully completed an independent, third-party audit assessment of smelter and refiner management systems and sourcing practices for responsible mineral procurement against Responsible Minerals Assurance Process standards. Based on the information obtained from these procedures, the Company has no reason to believe that any of the gold sourced during the Relevant Period originated in any of the Covered Countries. Therefore, in accordance with the Rule, the Company is not required to conduct a due diligence process or file a Conflict Minerals Report with respect to such conflict minerals. The Company's only obligation is to briefly describe both the reasonable country of origin inquiry it undertook and the corresponding results as set forth hereinabove.

This Conflict Minerals Disclosure is publicly available on the Company's website, located at *https://invest.clene.com/financial-information/sec-filings*. The information contained in or accessible from the Company's website is not incorporated into this Form SD and should not be considered part of this Form SD.

**Item 1.02 Exhibit**

Not applicable.

**Section 2** – **Resource Extraction Issuer Disclosure**

**Item 2.01 Resource Extraction Issuer Disclosure and Report**

Not applicable.

**Section 3** – **Exhibits**

**Item 3.01 Exhibits**

Not applicable.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

---

| | | |
|:---|:---|:---|
|  | CLENE INC. | CLENE INC. |
| Date: May 22, 2026 | By:  | /s/ Robert Etherington |
|  |  | Robert Etherington |
|  |  | President and Chief Executive Officer |

---